Evidence map›Paper›PMID 19545857›Full record

Trial reportBiological psychiatry2009

Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.

Rebecca B Price, Matthew K Nock, Dennis S Charney, Sanjay J Mathew

2 registry-linked trialsAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Biological psychiatry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 282 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
282citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02305394 phase4unknown statusnot on this mapstarted 2015, after this paper: background citation

Effect of Subanesthetic Dose of Ketamine Combined With Propofol on Cognitive Function in Depressive Patients Undergoing Electroconvulsive Therapy ---a Randomized Control Double-Blind Clinical Trial

TypeinterventionalSponsorFirst Affiliated Hospital of Chongqing Medical UniversityRan2015 to 2017Enrolled132ConditionsDepressive Symptoms, Impaired Cognition, Electroconvulsive TherapyArmsketamine and propofol, propofol and normal saline
NCT02783430 phase2 / phase3completednot on this mapstarted 2016, after this paper: background citation

Evaluation of the Initial Prescription of Ketamine and Milnacipran Forin Depression in Patients With a Progressive Disease

TypeinterventionalSponsorUniversity Hospital, LilleRan2016 to 2024Enrolled42ConditionsDepressionArmsKetamine, Milnacipran, Placebo
3 · Its place in the literature

Who cites it

282 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines.The international journal of neuropsychopharmacology · 2020
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

222 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rebecca B PriceDepartment of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA. rprice@eden.rutgers.edu
Matthew K Nock
Dennis S Charney
Sanjay J Mathew

Funding

ZIPRASIDONE (GEODON) AUGMENTATION IN SEROTONIN REUPTAKE INHIBITOR-RESISTANT OBM01RR000071 · NCRR · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI OHNUMA, TAKAO · 1985 to 2009
$41.5M
PROTON MRS STUDIES IN GENERALIZED ANXIETY DISORDERK23MH069656 · NIMH · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI MATHEW, SANJAY J · 2004 to 2008
$803k
Behavioral and fMRI correlates of late-life generalized anxiety disorderF31MH081468 · NIMH · RUTGERS, THE STATE UNIV OF N.J. · PI PRICE, REBECCA · 2008 to 2010
$70k
NCRR NIH HHS M01 RR000071NCRR NIH HHS MO1-RR-00071NIMH NIH HHS F31 MH081468NIMH NIH HHS K23 MH069656NIMH NIH HHS K23-MH-069656
6 · The paper itself

Abstract

backgroundIntravenous ketamine has shown rapid antidepressant effects in early trials, making it a potentially attractive candidate for depressed patients at imminent risk of suicide. The Implicit Association Test (IAT), a performance-based measure of association between concepts, may have utility in suicide assessment.

methodsTwenty-six patients with treatment-resistant depression were assessed using the suicidality item of the Montgomery-Asberg Depression Rating Scale (MADRS-SI) 2 hours before and 24 hours following a single subanesthetic dose of intravenous ketamine. Ten patients also completed IATs assessing implicit suicidal associations at comparable time points. In a second study, nine patients received thrice-weekly ketamine infusions over a 12-day period.

resultsTwenty-four hours after a single infusion, MADRS-SI scores were reduced on average by 2.08 points on a 0 to 6 scale (p < .001; d = 1.37), and 81% of patients received a rating of 0 or 1 postinfusion. Implicit suicidal associations were also reduced following ketamine (p = .003; d = 1.36), with reductions correlated across implicit and explicit measures. MADRS-SI reductions were sustained for 12 days by repeated-dose ketamine (p < .001; d = 2.42).

conclusionsThese preliminary findings support the premise that ketamine has rapid beneficial effects on suicidal cognition and warrants further study.

Indexed as

Suicide PreventionCohort StudiesDepressionDrug ResistanceExcitatory Amino Acid AntagonistsFemaleHumansInfusions, IntravenousKetamineMaleMiddle AgedPsychiatric Status Rating ScalesSuicideExcitatory Amino Acid AntagonistsKetamine

Identifiers

PMID19545857
PMCPMC2935847

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.